107 related articles for article (PubMed ID: 10066884)
1. Design and preparation of cyclopeptamine antifungal agents.
Klein LL; Li L
Curr Pharm Des; 1999 Feb; 5(2):57-71. PubMed ID: 10066884
[TBL] [Abstract][Full Text] [Related]
2. Total synthesis and antifungal evaluation of cyclic aminohexapeptides.
Klein LL; Li L; Chen HJ; Curty CB; DeGoey DA; Grampovnik DJ; Leone CL; Thomas SA; Yeung CM; Funk KW; Kishore V; Lundell EO; Wodka D; Meulbroek JA; Alder JD; Nilius AM; Lartey PA; Plattner JJ
Bioorg Med Chem; 2000 Jul; 8(7):1677-96. PubMed ID: 10976515
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B.
Debono M; Abbott BJ; Turner JR; Howard LC; Gordee RS; Hunt AS; Barnhart M; Molloy RM; Willard KE; Fukuda D
Ann N Y Acad Sci; 1988; 544():152-67. PubMed ID: 3063167
[No Abstract] [Full Text] [Related]
4. Novel echinocandin antifungals. Part 1: novel side-chain analogs of the natural product FR901379.
Tomishima M; Ohki H; Yamada A; Maki K; Ikeda F
Bioorg Med Chem Lett; 2008 Feb; 18(4):1474-7. PubMed ID: 18207736
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of a anti-fungal action of selected cyclic dipeptides.
Graz M; Jamie H; Versluis C; Milne P
Pharmazie; 2001 Nov; 56(11):900-1. PubMed ID: 11817182
[No Abstract] [Full Text] [Related]
6. Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin.
Tomishima M; Ohki H; Yamada A; Maki K; Ikeda F
Bioorg Med Chem Lett; 2008 May; 18(9):2886-90. PubMed ID: 18424132
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and biological evaluation of novel pseudomycin side-chain analogues. Part 2.
Chen SH; Sun X; Boyer R; Paschal J; Zeckner D; Current W; Zweifel M; Rodriguez M
Bioorg Med Chem Lett; 2000 Sep; 10(18):2107-10. PubMed ID: 10999481
[TBL] [Abstract][Full Text] [Related]
8. Total synthesis and structure-activity relationships of new echinocandin-like antifungal cyclolipohexapeptides.
Yao J; Liu H; Zhou T; Chen H; Miao Z; Sheng C; Zhang W
Eur J Med Chem; 2012 Apr; 50():196-208. PubMed ID: 22348827
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group.
Xu K; Huang L; Xu Z; Wang Y; Bai G; Wu Q; Wang X; Yu S; Jiang Y
Drug Des Devel Ther; 2015; 9():1459-67. PubMed ID: 25792806
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antimicrobial properties of non-hemolytic cationic alpha-cyclopeptoids.
Comegna D; Benincasa M; Gennaro R; Izzo I; De Riccardis F
Bioorg Med Chem; 2010 Mar; 18(5):2010-8. PubMed ID: 20153656
[TBL] [Abstract][Full Text] [Related]
11. Serum differentially alters the antifungal properties of echinocandin drugs.
Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
[TBL] [Abstract][Full Text] [Related]
12. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.
Schmatz DM; Abruzzo G; Powles MA; McFadden DC; Balkovec JM; Black RM; Nollstadt K; Bartizal K
J Antibiot (Tokyo); 1992 Dec; 45(12):1886-91. PubMed ID: 1490879
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
Zhao S; Zhao L; Zhang X; Liu C; Hao C; Xie H; Sun B; Zhao D; Cheng M
Eur J Med Chem; 2016 Nov; 123():514-522. PubMed ID: 27494168
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.
Wang W; Sheng C; Che X; Ji H; Miao Z; Yao J; Zhang WN
Arch Pharm (Weinheim); 2009 Dec; 342(12):732-9. PubMed ID: 19899102
[TBL] [Abstract][Full Text] [Related]
15. FR209602 and related compounds, novel antifungal lipopeptides from coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity.
Kanasaki R; Abe F; Furukawa S; Yoshikawa K; Fujie A; Hino M; Hashimoto S; Hori Y
J Antibiot (Tokyo); 2006 Mar; 59(3):145-8. PubMed ID: 16724454
[TBL] [Abstract][Full Text] [Related]
16. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
Li X; Hou Y; Yue L; Liu S; Du J; Sun S
Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
Liu P; Zhu S; Li P; Xie W; Jin Y; Sun Q; Wu Q; Sun P; Zhang Y; Yang X; Jiang Y; Zhang D
Bioorg Med Chem Lett; 2008 Jun; 18(11):3261-5. PubMed ID: 18467095
[TBL] [Abstract][Full Text] [Related]
18. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro antifungal evaluation of 2-(2,4-difluorophenyl)-1-[(1H-indol-3-ylmethyl)methylamino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.
Guillon R; Logé C; Pagniez F; Ferchaud-Roucher V; Duflos M; Picot C; Le Pape P
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):261-9. PubMed ID: 20695753
[TBL] [Abstract][Full Text] [Related]
20. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
